Liftstream is an executive search recruitment company in the life sciences sector
Companies to partner executive search firms which have elevated their D&I expertise, and explicitly request increased candidate diversity.
Flagship Pioneering today announced the appointment of industry veteran David Epstein to serve in the newly created role of Executive Partner. Epstein will join as a strategic resource to the firm that systematically conceives, creates, resources and grows first-in-category ventures to transform human health and sustainability. The appointment follows Flagship’s recent additions of industry leaders Dr. Michael Rosenblatt (formerly of Merck) as Chief Medical Officer and Jim Gilbert (formerly of Boston Scientific and Bain) as Senior Partner, and supports the firm’s goal of driving accelerated value growth within its portfolio companies.
“David is a leader and long-time pioneer within the pharma industry, having developed dozens of new medicines benefiting millions of patients around the world,” said Noubar Afeyan, Ph.D., founder and CEO of Flagship. “His progressive approach to science and business acumen gleaned over his tenured career in the pharmaceutical industry complements Flagship’s culture and team. We will apply his expertise broadly as we continue making and realizing the maximum potential of disruptive innovations that yield unprecedented therapies.”
Mr. Epstein’s first significant involvement within the Flagship portfolio will be as Chairman of the Board of Rubius Therapeutics, a venture founded and launched by the Flagship VentureLabs® innovation foundry to exploit the potential medical impact of endowing red blood cells with therapeutic properties. The company’s disruptive platform provides off-the-shelf, enucleated cell-based therapies that promise to treat a wide array of ailments including cancer and autoimmune, metabolic, and hematologic diseases.
“Flagship Pioneering is breaking boundaries and exploring new frontiers that, I believe, could dramatically improve the quality of human life,” said Epstein. “Joining Flagship’s disruptive innovation engine is an opportunity of a lifetime, and I welcome the opportunity to bring my passion for medicine, deep knowledge and ties to industry, and commitment to solving some of the world’s greatest health challenges to bear. In particular, I am tremendously excited by the promise of Rubius’ Red-Cell Therapeutics™ platform, as it portends the broad impact of off-the-shelf, precision cell therapies.”
Do you work in the Massachusetts Life Sciences sector? – Take the Human Capital Pipeline Survey https://www.liftstream.com/pipelinesurvey.html
Albumedix A/S announced on January 4th 2017 that it has appointed Dr. Giles Campion as Chief Medical Officer (CMO). Dr Campion brings with him more than 25 years’ experience in drug development from both large pharma and biotech companies having worked in senior development positions in the US as well as Europe.
Voyager Therapeutics, a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced the appointment of Jane Pritchett Henderson as senior vice president and chief financial officer effective January 1, 2017. Ms. Henderson brings more than 28 years of life sciences industry and banking experience and leadership to her new role.
Tris Pharma, a pharmaceutical company based in Monmouth Junction, New Jersey, has appointed Sharon Clarke to the position of Chief Commercial Officer to lead the firm’s brand business and launch its first commercial product. The firm has a robust portfolio of approved New Drug Applications and late-stage pipeline of innovative technology based product candidates for the treatment of Attention-Deficit Hyperactivity Disorder.
PhaseBio Pharmaceuticals, a clinical-stage biopharmaceutical company head-quartered in Malvern, PA, has appointed John Lee as Chief Medical Officer based in Malvern and John Sharp as Chief Financial officer based in San Diego.
aTyr Pharma, a San Diego-based biotherapeutics company addressing rare diseases, has appointed Sanjay Shukla as Chief Medical Officer. Shukla will lead aTyr’s clinical efforts to advance its Physiocrine biology therapeutic intervention points and develop medicines that promote tissue homeostasis for patients with rare diseases.
Trovagene, a cell-free molecular diagnostics company in San Diego, California, has terminated the employment of CEO Antonius Schuh and CFO Stephen Zaniboni for withholding new therapeutics in the field of precision medicine for their own benefit. The firm filed a complaint against Schuh and Zaniboni for breach of fiduciary duty, which was filed in the Superior Court of the State of California for the County of San Diego. The complaint requests Schuh and Zaniboni to turn over their interests in these new therapeutics to Trovagene.
Adaptive Biotechnologies, a sequencing and bioinformatics company based in Seattle, Washington, has appointed Diego Miralles as president of Adaptive Therapeutics. Miralles will build the Therapeutics Division of Adaptive, and head the company’s efforts to leverage its platform for identifying T- and B-cell receptors for use in therapies. He will provide both scientific and commercial guidance to the existing and future programs and partnerships that Adaptive is implementing